GW-501516

Intro

Cardarine (GW-501516) is a synthetic PPARδ agonist developed jointly by GlaxoSmithKline and Ligand Pharmaceuticals in the late 1990s as a treatment for hyperlipidemia and metabolic syndrome.

It binds the peroxisome proliferator-activated receptor delta (PPARδ) with exceptional potency (EC50 = 1.2 nM) and selectivity (>1000-fold over PPARα and PPARγ).

Cardarine is not a SARM. It has zero androgen receptor activity. The 'SARM' label is a persistent market misclassification — cardarine's mechanism is entirely through the PPARδ nuclear receptor pathway, which regulates fatty acid oxidation gene expression rather than muscle protein synthesis.

In human clinical trials (doses 2.5–10 mg/day, durations 2–12 weeks), cardarine produced meaningful lipid improvements — HDL +16.9%, triglycerides −30%, LDL −7.3% — and upregulated CPT1b expression in skeletal muscle, confirming the mechanism operates in humans at therapeutic doses. No significant adverse events were reported in any human trial.

Development was terminated in 2007 when 2-year rodent carcinogenicity studies revealed tumor acceleration across multiple organ systems. The exact mechanism is believed to involve PPARδ-driven cell proliferation — the same pathway that benefits fat oxidation may, under sustained activation, promote tumor growth in pre-cancerous cells. The scientific literature now contains ~27 studies on cardarine and cancer with conflicting findings: some studies show pro-tumor effects, others show anti-tumor or neutral effects, particularly in different tissue contexts (e.g., anti-tumor in pancreatic cancer vs. pro-proliferative in colorectal cancer). This ambiguity makes the cancer risk genuinely difficult to quantify.

The community has used cardarine continuously since the mid-2000s despite this history, rationalizing the risk based on scale arguments (animal doses far exceed human doses) and absence of documented human cancer cases. This rationalization deserves scrutiny — community doses of 10–20 mg/day are lower than the rodent cancer-causing doses but not by as large a margin as commonly believed when human equivalent dose calculations are applied.

Observed Effects

Endurance and Stamina (High Confidence) The most consistent and prominent reported effect. Community users across combat sports, bodybuilding, and endurance athletics describe meaningful improvement in sustained work capacity within 1–2 weeks of starting cardarine. Specific reports include completing full BJJ sessions without gassing in final rounds, reducing mile times by 30 seconds on 20 mg/day, and pushing harder in conditioning blocks without hitting the anaerobic wall. Mechanistically, this reflects the shift in skeletal muscle fuel use toward fatty acid oxidation — sparing glycogen and reducing the rate of lactate accumulation during moderate-intensity work.

Human clinical data confirms CPT1b (carnitine palmitoyltransferase 1b, the rate-limiting enzyme for fatty acid entry into mitochondria) is upregulated in skeletal muscle at therapeutic doses, providing mechanistic grounding for the community endurance reports.

Fat Oxidation and Body Composition (Moderate-High Confidence) Fat loss is secondary to endurance improvement and appears more gradually (weeks 3–4). Most credible in the context of a caloric deficit — cardarine promotes fat oxidation as the primary fuel source and community reports of 8 lbs fat loss over 8 weeks on cardarine + deficit diet are plausible given the mechanism. A 12-week RCT in 268 subjects showed triglyceride reduction of −16.9% alongside HDL improvement of +16.9%, confirming the lipid-modifying arm of fat metabolism is clinically active.

Ketogenic-diet users report improved late-session training quality and pump despite very low carbohydrate intake (70g/day), suggesting cardarine helps maintain performance in glycogen-depleted states by enhancing fatty acid utilization efficiency.

Lipid Profile Improvement (High Confidence, Clinically Validated) HDL +16.9%, triglycerides −16.9% (12-week RCT, n=268); fasting triglycerides −30%, liver fat −20%, fasting insulin −11% (2-week RCT, n=18 obese men). These are among the most robust human clinical effects in the SARM/PPARδ agonist category — well-controlled RCT data, not anecdote.

This makes cardarine clinically interesting for managing the adverse lipid effects of AAS stacks (which commonly worsen HDL/LDL ratios and elevate triglycerides). Community use for this purpose is well-established.

No Strength Effect Multiple community sources and experienced users explicitly note zero strength improvement. The mechanism is metabolic/cardiovascular — PPARδ does not drive protein synthesis or androgen receptor activity. Users who ran both RAD-140 and cardarine confirm cardarine contributes nothing to strength or lean mass.

Cardiovascular Regeneration (Emerging, Preclinical) Han et al. (2023) demonstrated that PPARδ activation with cardarine activates endothelial progenitor cells to induce angiomyogenesis through MMP-9-mediated IGF-1 paracrine networks. This suggests potential cardiovascular regenerative effects beyond fat oxidation — a distinct benefit pathway not yet validated in community protocols but mechanistically plausible.

Field Reports

The consistent thread across community experience reports is the distinctness and speed of the endurance response.

Users across combat sports, HIIT, and steady-state endurance work describe the effect as qualitatively different from other compounds — not just improved cardiovascular efficiency or heart rate management, but an ability to maintain high-intensity work capacity into the late stages of sessions where they would previously gas out.

A blinded n=1 self-experiment (Flash Forward podcast) showed a 30-second mile time improvement on 20 mg/day at week 4, with regression post-washout — methodologically limited but directionally consistent with mechanism. Polish BJJ practitioners report sustainable performance through full 90-minute sessions, appearing within the first week. UK-Muscle users describe microdosing at 10 mg/day as sufficient for conditioning work improvement without using the high end of the community dose range.

Fat loss reports are less dramatic — cardarine users on deficit describe gradual body composition changes over weeks 3–4, with noted specificity toward 'stubborn' fat areas. The compound does not create a deficit but meaningfully changes what fuel is burned once in one.

An important observation from community data: athletes who have used both RAD-140 and cardarine are unambiguous that cardarine adds nothing to strength or lean mass — the benefit is entirely metabolic and cardiovascular. This is expected from mechanism but important to set user expectations correctly.

The ketogenic diet + cardarine combination appears in multiple reports as a high-synergy stack — cardarine maintains training quality in glycogen-depleted states where other users would experience early performance drops. The late-week pump and performance reports from keto users are mechanistically explained by enhanced fat oxidation capacity compensating for the deliberately restricted carbohydrate substrate.

Contest prep bodybuilders describe cardarine as the conditioning compound — the thing that keeps cardiovascular performance and fat-burning capacity online during aggressive caloric restriction and high AAS loads that would otherwise compromise cardio output.

Community Consensus

Cardarine has been in continuous community use since the mid-2000s, predating its WADA ban. It gained early traction among combat sports athletes and endurance performers who paid premium prices (~$1,000/month) for access before it became widely commercially available. The 2008 Beijing Olympics reportedly saw early detection of cardarine use among athletes, which accelerated the 2009 WADA ban.

The persistent misclassification as a 'SARM' reflects the retail reality — cardarine is marketed alongside SARMs and sold by the same product ecosystem, leading to category confusion that has proven nearly impossible to correct in popular discourse. Community educators consistently have to open cardarine discussions with a classification correction.

The cancer debate has been central to cardarine's community identity since the GSK halt became widely known. The community's response is largely risk-rationalization: (1) scale argument — rodent doses are higher than human doses on a mg/kg basis; (2) outcome argument — no human cancer cases documented in 15+ years of community use; (3) uncertainty argument — the scientific literature is conflicting, not uniformly condemning. This rationalization is partially reasonable but is vulnerable to the point that the margin between rodent cancer-causing doses and community doses is smaller than many users believe, and the mechanism that causes cancer is the same mechanism that provides benefit.

The community has essentially decided that the risk is acceptable given the benefits, absence of alternatives with the same endurance profile, and absence of documented human harm. This is an adult risk decision only when the carcinogenicity uncertainty is taken seriously rather than dismissed.

GW-0742 has emerged in advanced community discussions as a potential safer successor with a potentially different carcinogenicity profile. However, GW-0742 has essentially no community track record relative to cardarine's 15+ years of human data.

Risks & Monitoring

Cancer Risk (Critical — Unresolved) The dominant adverse effect concern. GSK terminated all clinical trials in 2007 after 2-year rat and mouse studies showed acceleration of tumor formation across multiple organ systems.

The mechanism is PPARδ-driven — the same receptor activation that upregulates fatty acid oxidation genes can, in pre-cancerous cells, promote proliferation and accelerate tumor progression.

The scientific literature on cardarine and cancer contains ~27 studies with genuinely conflicting results. Some studies show pro-tumor effects (particularly in colorectal, skin, and liver models). Others show anti-tumor or neutral effects (pancreatic, prostate contexts). The net picture is ambiguous at the mechanistic level — it is not simply a dose issue. Community speakers with access to the primary literature explicitly state: 'the cancer-inducing dose might be lower than commonly thought' and 'the evidence is highly conflicting.'

Human cancer cases attributable to cardarine are not documented in the medical literature. The risk is extrapolated from rodent models. However, absence of documented cases may reflect limited human exposure duration and follow-up, not absence of risk.

Dose context: Standard community doses (10–20 mg/day) are below the doses used in rodent carcinogenicity studies when adjusted for body weight using standard human equivalent dose (HED) scaling. However, the margin is smaller than the community typically represents — see the Geared Coaching and community speaker analyses that put the HED of the rodent cancer-causing doses at approximately 258 mg/day for a 190 lb person, meaning the 10–20× margin is real but not as large as when raw mg/kg comparisons are made without scaling.

Detection Time (Relevant for Tested Athletes) Cardarine and its metabolites are detectable for several weeks after last use due to slow elimination kinetics. WADA-prohibited since 2009; WADA issued an explicit health warning in 2013 citing the carcinogenicity concern specifically — this is not a standard doping ban based on performance advantage alone.

Minimal Clinical Side Effect Profile (Within Trial Range) Human clinical trials at 2.5–10 mg/day for up to 12 weeks: no significant changes in body weight, blood pressure, insulin levels, or other safety markers. No significant adverse events were reported across any dose group or duration.

GI Tolerance Generally well-tolerated. A minority of community users report mild nausea at 20 mg doses when taken fasted; resolved by taking with food. No significant GI adverse event pattern.

Theoretical Cancer-Risk Interactions In immunocompromised individuals or those with active or prior cancer history, combining cardarine with other pro-proliferative compounds (e.g., IGF-1 LR3, GH) may amplify the theoretical carcinogenicity risk. No direct data — theoretical reasoning based on mechanism.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Endurance Performance (Combat Sports / HIIT / Cardio Optimization) Cardarine 10–20 mg/day for 6–8 weeks, timed 30–60 minutes pre-training.

No other compound required. Optional: AICAR 10–15 mg subcutaneous + injectable L-carnitine for synergistic triple-mechanism endurance stack (AICAR → AMPK; cardarine → PPARδ; L-carnitine → fatty acid transport). Cycle off for equal time before repeating.

Fat Loss (Deficit Protocol) Cardarine 20 mg/day for 8–10 weeks in caloric deficit. The compound does not create a caloric deficit — it shifts substrate utilization toward fat once in deficit. Optional addition: Ostarine 10–15 mg/day to preserve lean mass during aggressive cut. Stack with injectable L-carnitine for enhanced fatty acid mobilization.

GH Stack Insulin Resistance Mitigation Cardarine 10 mg/day co-administered with high-dose GH or GH secretagogue protocol (MK-677, ipamorelin + CJC-1295). GH/GHS induces lipolysis → elevated free fatty acids → cardarine addresses downstream metabolic stress and maintains insulin sensitivity. Considered by community speakers as the primary clinical justification for 10 mg/day dosing based on clinical trial evidence.

AAS Lipid Management (Contest Prep) Cardarine 20 mg/day for the final 8 weeks of an AAS contest prep cycle. Addresses the HDL suppression and TG elevation caused by anabolic steroids. Widely used in contest prep community for maintaining cardiovascular health markers during AAS cycles.

Retatrutide / GLP-1 Combination Some community protocols combine cardarine with retatrutide (10–20 mg) for compound fat-loss effect — GLP-1/GIP/glucagon agonism reduces intake and hepatic fat; cardarine enhances peripheral fat oxidation. Community guide explicitly suggests this combination for 'greater results.' No specific clinical data on the combination.

Dosing Details

Standard community range: 10-20 mg/day The community standard dose range overlaps the upper bound of human clinical trial doses.

Most users report 10-20 mg covers the endurance and fat oxidation effects without meaningful additional benefit from higher doses in the typical cycle length.

Single daily dose vs. split Half-life is approximately 16-24 hours with ~50% bioavailability. A single daily dose is common. Pre-workout timing is a convention rather than a pharmacokinetic requirement, because cardarine does not require exercise to activate its metabolic effects.

Twice-daily training pattern (40 mg/day) Some athletes training twice per day report 20 mg before each session, totaling 40 mg/day. This is outside clinical trial ranges and carries higher theoretical risk relative to the standard community range.

Cycle length: 6-8 weeks typical, 12 weeks upper community boundary The community consensus for cycle length is 6-8 weeks, with 12 weeks treated as the hard upper boundary by those who extend. Longer cycles increase cumulative exposure at a time when the carcinogenicity risk profile is most relevant.

Minimum threshold: ~10 mg/day Clinical data used 2.5-10 mg/day; community data suggests 10 mg/day is the threshold for reliable endurance and fat oxidation effects at typical cycle durations. Subclinical doses below 5 mg may produce some lipid improvement but are unlikely to deliver the stamina benefits users seek.

Solo vs. stacked Cardarine appears as a standalone compound and is fully non-suppressive; no AI, HCG, or PCT is tied to cardarine itself. The limiting issue is the cancer-risk uncertainty, not endocrine recovery.

Stacks & Alternatives

Synergistic endurance triple-mechanism stack — AICAR activates AMPK → mitochondrial biogenesis and fatty acid transport capacity; cardarine activates PPARδ → fat oxidation gene expression. The two pathways converge on mitochondrial function and fat oxidation but through distinct nodes, producing additive endurance effects without redundancy.

Facilitates fatty acid transport into the mitochondrial matrix (carnitine shuttle). Combines with cardarine's CPT1b upregulation for enhanced fatty acid oxidation throughput. Community speakers recommend injectable L-carnitine (or L-carnitine L-tartrate) as a standard co-supplement with cardarine.

Classic cut stack — Ostarine preserves lean mass during caloric deficit while cardarine drives fat oxidation and maintains conditioning performance. Both are non-suppressive at standard doses; no PCT required for most users.

Recomposition stack — LGD-4033 drives lean mass gain, Ostarine preserves/adds mass, cardarine handles fat oxidation and conditioning. Community-documented in multiple sources including Finnish language reviews. Note: LGD-4033 is suppressive; PCT required after this stack.

GH secretagogue + PPARδ agonist combination — MK-677 elevates GH/IGF-1 with pro-anabolic and nutrient partitioning effects; cardarine addresses the insulin resistance that high-dose GH secretagogues can produce. Synergistic for body recomposition.

GLP-1/GIP/glucagon triple agonist combined with cardarine for compound fat loss — retatrutide reduces caloric intake and hepatic fat; cardarine enhances peripheral fat oxidation. Community data is limited but the mechanistic rationale is sound.

Alternatives

Stack Cost

Practical Setup

The Cancer Risk Decision Using cardarine requires genuine informed risk acceptance, not rationalization.

The GSK development halt was based on real carcinogenicity data. The mechanism that causes the carcinogenicity concern is the same mechanism that provides the endurance and fat-burning benefit. The science is ambiguous — not simply 'dose-dependent' as commonly stated, but genuinely conflicting across tissue contexts. Community speakers with deep literature knowledge explicitly warn that cancer-risk markers and cycle limits matter. This remains reported practice and risk framing, not reader-specific clearance to use.

No PCT Required Cardarine is fully non-suppressive — no androgen receptor activity, no HPG axis disruption. No PCT, AI, or HCG is tied to cardarine itself. This is a meaningful practical advantage over SARMs and AAS where suppression management adds cost and complexity.

Stacking Flexibility Cardarine's non-hormonal mechanism means it is commonly stacked with AAS, SARMs, GH secretagogues, and peptides. No pharmacokinetic conflicts are documented, but broad compatibility does not remove the carcinogenicity uncertainty.

Timing and Bioavailability Oral administration, ~50% bioavailability, ~16-24 hour half-life. Single daily dosing is common due to the long half-life. Pre-workout timing is a community convention, while consistent daily timing is the more pharmacokinetically relevant factor.

Drug Testing Long detection window — cardarine metabolites are detectable for multiple weeks after last dose. Tested athletes face a permanent WADA prohibition with no exemption pathway; the health warning attached to the ban signals that WADA views this as a safety issue, not just a competitive fairness issue.

Product Quality As a research chemical, quality varies significantly. Underdosed, contaminated, or mislabeled product may fail to deliver the expected endurance effect, which is one common explanation for 'it didn't work for me' reports. Lot-level identity and purity documentation matter.

Mechanism Deep Dive

Primary Mechanism: PPARδ Agonism PPARδ (peroxisome proliferator-activated receptor delta) is a nuclear receptor expressed predominantly in skeletal muscle, heart, and adipose tissue.

Upon activation, PPARδ heterodimerizes with RXR (retinoid X receptor) and drives transcription of fatty acid oxidation genes. GW-501516 binds PPARδ with EC50 = 1.2 nM and selectivity >1000-fold over PPARα and PPARγ — meaning it specifically activates the delta receptor without meaningful crosstalk to the others.

Skeletal Muscle Fuel Switch In skeletal muscle, PPARδ activation upregulates: - CPT1b (carnitine palmitoyltransferase 1b): the rate-limiting step for long-chain fatty acid transport into the mitochondrial matrix - MCAD (medium-chain acyl-CoA dehydrogenase): key beta-oxidation enzyme - ABCA1 (ATP-binding cassette transporter A1): reverse cholesterol transport - Acyl-CoA oxidase: peroxisomal fatty acid oxidation

The net effect measured in isolated human skeletal muscle: palmitate oxidation (fat) +46% at 1 μmol/L GW-501516, glucose oxidation −46% at the same dose. The muscle switches from carbohydrate-dominant to fat-dominant fuel use. This increases endurance capacity by sparing muscle glycogen and reducing the rate of anaerobic lactate production during sustained moderate-intensity work.

Type I Fiber Remodeling (Animal Data) In mouse models, continuous PPARδ activation produced a slow-twitch (Type I) fiber shift — increasing the proportion of fatigue-resistant oxidative fibers relative to fast-twitch glycolytic fibers. This structural adaptation would amplify the biochemical fuel-switch effect over sustained use. Whether this fiber remodeling occurs at community cycle lengths (6–12 weeks) in humans is unestablished.

Hepatic AMPK/PGC-1α/Lipin1 Pathway In the liver, PPARδ activation drives an AMPK → PGC-1α → Lipin1 cascade, increasing mitochondrial number and fat oxidation capacity hepatically. This contributes to the observed 20% reduction in liver fat in the 2-week RCT and provides mechanistic grounding for the triglyceride-lowering effects.

MMP-9/IGF-1 Paracrine Angiomyogenesis (Emerging) Han et al. (2023) demonstrated PPARδ activation with cardarine stimulates angiomyogenesis through MMP-9 (matrix metalloproteinase 9) mediated IGF-1 paracrine signaling in endothelial progenitor cells. This pathway could underlie cardiovascular regenerative effects — formation of new blood vessels and muscle tissue. This is a distinct downstream effect from the fat oxidation pathway and was not a focus of the original clinical development program.

The Carcinogenicity Mechanism PPARδ is a cell proliferation regulator in multiple tissue types beyond muscle. In certain tumor and pre-tumor cell contexts, PPARδ activation promotes cell survival, proliferation, and angiogenesis — the same angiomyogenic capacity that may benefit cardiac tissue can promote tumor vascularization and growth. This is the biologically plausible mechanism for the rodent carcinogenicity signal. The ~27 studies in the literature confirm this dual PPARδ biology: anti-tumor in some contexts (pancreatic cancer, certain in vitro conditions), pro-tumor in others (colorectal adenoma, skin tumor models, some liver models). The net oncological risk in humans at community doses over short cycles cannot be determined from available data.

Evidence Index